ArticleDrug metabolism and disposition: the biological fate of chemicals2017
In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s.
Open access · bronzeAbstract read
In one paragraph
Article in Drug metabolism and disposition: the biological fate of chemicals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.Pharmacology & therapeutics · 2020Pooled it
- Marizomib in the therapy of brain tumors-how far did we go and where do we stand?Pharmacological reports : PR · 2025Review
- Tissue-, Region-, and Gene-Specific Induction of Microsomal Epoxide Hydrolase Expression and Activity in the Mouse Intestine by Arsenic in Drinking Water.Drug metabolism and disposition: the biological fate of chemicals · 2024Article
- A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma.Journal of analytical methods in chemistry · 2023Article
- Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.International journal of molecular sciences · 2021Review
- Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.Pharmaceutical research · 2020Article
- Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.Expert opinion on drug metabolism & toxicology · 2019Review
- Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.Journal of medicinal chemistry · 2019Article
- Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.British journal of clinical pharmacology · 2019Article
- Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.Journal of the American Chemical Society · 2018Article
- Next-generation proteasome inhibitors for cancer therapy.Translational research : the journal of laboratory and clinical medicine · 2018Review
- 1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology.Medicinal chemistry · 2018Article
- Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.Archives of toxicology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Zhican WangDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Ying FangDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Juli TeagueDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Hansen WongDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Christophe MorisseauDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Bruce D HammockDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Dan A RockDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.).
Zhengping WangDepartment of Pharmacokinetics and Drug Metabolism (Zhi.W., Y.F., D.A.R., Zhe.W.), and Clinical Pharmacology Modeling and Simulation (H.W.), Amgen Inc., South San Francisco, California; Drug Metabolism and Pharmacokinetics, Onyx Pharmaceuticals, an Amgen Subsidiary, South San Francisco, California (J.T.); and Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California (C.M., B.D.H.) zwang687@gmail.com.
University of California, Davis · USUC Davis Comprehensive Cancer CenterAmgen (United States) · US
Funding
Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1MVITAMIN C (ASCORBATE) METABOLISM IN DROSPHILA MELANOGASTERP41RR013461 · NCRR · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI ALLEN, LINDSAY H · 1999 to 2011
$20.8MHYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0MNCRR NIH HHS P41 RR013461NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R01 ES002710
Abstract
Oprozomib is an oral proteasome inhibitor currently under investigation in patients with hematologic malignancies or solid tumors. Oprozomib elicits potent pharmacological actions by forming a covalent bond with the active site
Indexed as
Administration, OralAdultChlorpromazineCytochrome P-450 Enzyme SystemDrug InteractionsEpoxide HydrolasesFemaleHalf-LifeHepatocytesHumansMaleMicrosomes, LiverMiddle AgedOxidation-ReductionProteasome InhibitorsRecombinant Proteins1-aminobenzotriazoleChlorpromazineCytochrome P-450 Enzyme SystemEpoxide HydrolasesopromazineProteasome InhibitorsRecombinant ProteinsTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.